# US 2025/0334579 A1 · Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for detection and treatment monitoring

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0334579 A1
- Document ID: US20250334579A1
- Status: Published application
- Kind: A1
- Application number: 19/085,892
- Filed: 2025-03-20
- Published: 2025-10-30
- Earliest claimed: 2016-12-30
- Assignees: THE METHODIST HOSPITAL, dba HOUSTON METHODIST
- Applicants: THE METHODIST HOSPITAL, dba HOUSTON METHODIST
- Inventors: Ye Hu; Jia Fan; Kai Liang; Fei Liu; Dali Sun
- Web page: https://patentgrep.com/patent/US20250334579A1

## CPC

- G01N 33/57525: of the liver or pancreas
- G01N 33/5432: {Liposomes or microcapsules}
- G01N 33/54346: {Nanoparticles}
- G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μL of plasma is described herein. This assay uses binding of gold nanospheres and nanorods with EV- and tumor-derived EV-specificities to produce a local plasmon effect that enhances tumor-derived EV detection sensitivity and specificity. This nPES approach is also a non-invasive method for assessing pancreatic cancer stage and treatment response that can be easily refined for clinical use, and is readily adapted for diagnosis and monitoring of other conditions with disease-specific EV proteins.

## Claims

### Claim 1

A method of detecting a pancreatic cancer specific protein, ephrin type-A receptor 2 (EphA2), comprising:
contacting a sample comprising an extracellular vesicle (EV) with a surface conjugated with a first antibody directed to a first molecule on the EV to capture the EV on the surface;
removing the remainder of the sample from the surface to generate separated EV captured on the surface;
incubating the separated EV captured on the surface with a first set of nanoparticles conjugated with a second antibody directed to EphA2 on the EV; and
detecting whether the pancreatic cancer specific protein, EphA2, is present in the sample by detecting binding between the second antibody and the EV.

### Claim 2 (depends on 1)

The method of claim 1, wherein the contacting further comprises conjugating the surface with the first antibody, and/or wherein the first molecule on the EV is selected from the group consisting of CD63, CD81, CD9, CD24, CD26, CD10, tumor susceptibility gene 101 (TSG101), heat shock 70 kDa protein 4 (HSP70), Rab-5b, programmed cell death 6-interacting protein (AIP1/Alix), aquaporin 2 (AQP2), vascular endothelial growth factor receptor 1 (FLT1), N-glycan containing a fucose residue, phosphocholine, phosphatidylserine, and sphingomyelin.

### Claim 3 (depends on 1)

The method of claim 1, wherein the incubating further comprises incubating the separated EV captured on the surface with a second set of nanoparticles conjugated with a third antibody directed to a second molecule on the EV, wherein:
the second molecule on the EV is selected from the group consisting of CD63, CD81, CD9, CD24, CD26, CD10, TSG101, HSP70, Rab-5b, AIP1/Alix, AQP2, FLTI, N-glycan containing a fucose residue, phosphocholine, phosphatidylserine, and sphingomyelin; and/or
the nanoparticles comprise a plurality of nanospheres, a plurality of nanorods, or a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the detecting comprises detecting binding between the second antibody and the EV and detecting binding between the third antibody and the EV.

### Claim 5 (depends on 4)

The method of claim 4, wherein dual binding of the two antibody-conjugated nanoparticles to the EV produces nanoplasmons and said nanoplasmons are detected.

### Claim 6 (depends on 3)

The method of claim 3, wherein the nanoparticles comprise gold.

### Claim 7 (depends on 3)

The method of claim 3, wherein the first antibody is different from the third antibody.

### Claim 8 (depends on 3)

The method of claim 3, wherein the first antibody is the same as the third antibody.

### Claim 9 (depends on 3)

The method of claim 3, wherein the first nanoparticle is different from the second nanoparticle.

### Claim 10

A method of diagnosing pancreatic cancer in a subject, comprising:
contacting a sample comprising an extracellular vesicle (EV) with a surface conjugated with a first antibody directed to a first molecule on the EV to capture the EV on the surface;
removing the remainder of the sample from the surface to generate separated EV captured on the surface;
incubating the separated EV captured on the surface with a first set of nanoparticles conjugated with a second antibody directed to EphA2; and
detecting whether pancreatic cancer is present in the subject by detecting binding between the second antibody and the EV.

### Claim 11 (depends on 10)

The method of claim 10, wherein the contacting further comprises conjugating the surface with the first antibody, and/or wherein the first molecule on the EV is selected from the group consisting of CD63, CD81, CD9, CD24, CD26, CD10, tumor susceptibility gene 101 (TSG101), heat shock 70 kDa protein 4 (HSP70), Rab-5b, programmed cell death 6-interacting protein (AIP1/Alix), aquaporin 2 (AQP2), vascular endothelial growth factor receptor 1 (FLT1), N-glycan containing a fucose residue, phosphocholine, phosphatidylserine, and sphingomyelin.

### Claim 12 (depends on 10)

The method of claim 10, wherein the incubating further comprises incubating the separated EV captured on the surface with a second set of nanoparticles conjugated with a third antibody directed to a second molecule on the EV, wherein:
the second molecule on the EV is selected from the group consisting of CD63, CD81, CD9, CD24, CD, 26, CD10, TSG101, HSP70, Rab-5b, AIP1/Alix, AQP2, FLT1, N-glycan containing a fucose residue, phosphocholine, phosphatidylserine, and sphingomyelin; and/or
the nanoparticles comprise a plurality of nanospheres, a plurality of nanorods, or a combination thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the detecting comprises detecting binding between the second antibody and EV and detecting binding between the third antibody and the EV.

### Claim 14 (depends on 13)

The method of claim 13, wherein dual binding of the two antibody-conjugated nanoparticles to the EV produces nanoplasmons and said nanoplasmons are detected.

### Claim 15 (depends on 12)

The method of claim 12, wherein the nanoparticles comprise gold.

### Claim 16 (depends on 12)

The method of claim 12, wherein the first antibody is different from the third antibody.

### Claim 17 (depends on 12)

The method of claim 12, wherein the first antibody is the same as the third antibody.

### Claim 18 (depends on 12)

The method of claim 12, wherein the first nanoparticle is different from the second nanoparticle.

### Claim 19

A method of detecting a pancreatic cancer specific protein, ephrin type-A receptor 2 (EphA2), comprising:
contacting a sample comprising an extracellular vesicle (EV) with a first antibody directed to a first molecule on the EV to generate an antibody-bound EV;
separating the antibody-bound EV from the remainder of the sample to generate a separated antibody-bound EV;
incubating the separated antibody-bound EV with a first set of nanoparticles conjugated with a second antibody directed to EphA2 on the EV; and
detecting whether EphA2 is present in the sample by detecting binding between the second antibody and the EV.

### Claim 20 (depends on 19)

The method of claim 19, wherein the first antibody is conjugated to a surface, and wherein the separating comprises removing the remainder of the sample from the surface.
